GM
DAWN

GeoWealth Management’s Day One Biopharmaceuticals DAWN Stock Holding History

GeoWealth Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23
Closed -$150 – 863
2025
Q2 		$150 Buy
+23
New +$158 ﹤0.01% 1196

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

GeoWealth Management's DAWN Position: Q3 2025 in Review

GeoWealth Management sold out of Day One Biopharmaceuticals (DAWN) in Q3 2025, closing a stake of 23 shares — an estimated $150 sold.

GeoWealth Management first reported a position in DAWN in Q2 2025 and held it in 1 quarter. The position peaked at $150 in Q2 2025. 172 funds tracked by Wall St. Rank hold DAWN as of Q3 2025.

  • GeoWealth Management reported no remaining Day One Biopharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • GeoWealth Management sold 23 Day One Biopharmaceuticals shares in Q3 2025, an estimated $150.
  • GeoWealth Management first reported a position in Day One Biopharmaceuticals in Q2 2025 and held it in 1 quarter.
  • GeoWealth Management's Day One Biopharmaceuticals position peaked at $150 in Q2 2025.
  • 172 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2025.

Based on GeoWealth Management's 13F filing for Q3 2025, filed 13 Nov 2025.